Bcma binding molecules and methods of use thereof
AssigneeKite Pharma, Inc.
InventorsJed WILTZIUS, Ruben ALVAREZ RODRIGUEZ, Jonathan BELK
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
Claims20
A polypeptide comprising an antigen binding molecule that specifically binds to B-cell maturation antigen (BCMA), wherein the antigen binding molecule comprises a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 399;
- a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 400;
- a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 401;
- a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 404;
- a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 405;
- and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 406.
Dependencies are inferred from the claim text.